Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Nantes – page 79

954 clinical trials in Nantes, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Nantes at a glance
954
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

954 trials in Nantes

Open in trial search

Study of isatuximab and pegenzileukin combination treatment for patients with relapsed or refractory multiple myeloma who previously received anti-CD38 and anti-BCMA therapy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Isatuximab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Plasma cell myeloma

Not recruiting

Study Comparing Selinexor, Pomalidomide, and Dexamethasone with Elotuzumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:European Myeloma Network B.V.

Ovarian cancer+1

Not recruiting

Study of OSE2101 vaccine alone or with pembrolizumab as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer after chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:MPS-102
  • Sponsor:Arcagy Gineco

Study on Rituximab and Cyclophosphamide for Patients with Severe Mucous Membrane Pemphigoid

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Glucose
  • Sponsor:Centre Hospitalier Universitaire Rouen

Plasma cell myeloma

Not recruiting

Study on Isatuximab, Lenalidomide, and Dexamethasone for Elderly Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Bortezomib
  • Sponsor:Centre Hospitalier Universitaire De Poitiers

Acute myeloid leukaemia+1

Not recruiting

Study of ASTX727 and Donor Lymphocyte Infusions for Patients with High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia After Stem Cell Transplant

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cedazuridine
  • Sponsor:Groupe Francophone Des Myelodysplasies

Mantle cell lymphoma

Not recruiting

Study on Obinutuzumab, Venetoclax, and Ibrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Breast cancer+2

Not recruiting

Study of Durvalumab, Olaparib, and Fulvestrant for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer with Specific Genetic Alterations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Unicancer

Dermatitis atopic

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib and Dupilumab for Children Aged 2 to 12 with Moderate to Severe Atopic Dermatitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Dupilumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Cervix carcinoma

Not recruiting

Study on Atezolizumab, Bevacizumab, and Chemotherapy for Patients with Advanced Cervical Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer Ginecologico

Study on Improving Survival in Acute Myeloid Leukemia for Adults Aged 18-60 Using Idarubicin, Daunorubicin, Cytarabine, and Mycophenolic Acid

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Cytarabine
  • Sponsor:Centre Hospitalier Universitaire D'Angers

Cardiac arrest

Not recruiting

Study of Hydrocortisone and Vasopressin (Argipressin) Treatment in Adult Patients with Post-Cardiac Arrest Syndrome and Hemodynamic Failure

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Argipressin
  • Sponsor:Assistance Publique Hopitaux De Paris

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Nantes

What the registry says about research in the country

01 Oncology and Hematology

Advanced research focusing on multiple myeloma, leukemia, and various lymphomas. Studies are evaluating novel treatment combinations and therapeutic approaches for blood cancers.

  • Multiple Myeloma Treatments
  • Lymphoma Therapies
  • Leukemia Management

Innovative trials exploring combinations of targeted therapies and immunotherapies to improve patient outcomes.

02 Infectious Diseases

Comprehensive studies on preventive measures against viral infections, including trials for vaccines targeting CMV, yellow fever, and mpox.

  • Vaccine Development
  • Viral Prevention
  • Immunization Studies

Focus on developing and evaluating new vaccine formulations and delivery methods.

03 Autoimmune Conditions

Research investigating treatments for inflammatory bowel diseases and multiple sclerosis, including innovative approaches like fecal microbiota transplantation.

  • Crohn's Disease
  • Ulcerative Colitis
  • MS Treatment Strategies

Exploring novel therapeutic options and treatment de-escalation strategies.

04 Critical Care Medicine

Studies addressing postoperative care and management of severe conditions in intensive care settings, including burns and immune suppression.

  • Post-Surgery Care
  • Burn Treatment
  • ICU Interventions

Evaluating new approaches to improve patient comfort and outcomes in critical care.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.